- Home
- DAVA vs FTRE Comparison
DAVA vs FTRE Comparison
Compare DAVA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- FTRE
- Stock Information
- Founded
- DAVA 2000
- FTRE 1996
- Country
- DAVA United Kingdom
- FTRE United States
- Employees
- DAVA N/A
- FTRE N/A
- Industry
- DAVA EDP Services
- FTRE Medical Specialities
- Sector
- DAVA Technology
- FTRE Health Care
- Exchange
- DAVA Nasdaq
- FTRE Nasdaq
- Market Cap
- DAVA 761.0M
- FTRE 701.9M
- IPO Year
- DAVA 2018
- FTRE N/A
- Fundamental
- Price
- DAVA $9.85
- FTRE $10.13
- Analyst Decision
- DAVA Buy
- FTRE Hold
- Analyst Count
- DAVA 9
- FTRE 9
- Target Price
- DAVA $22.89
- FTRE $12.06
- AVG Volume (30 Days)
- DAVA 1.6M
- FTRE 1.9M
- Earning Date
- DAVA 09-04-2025
- FTRE 11-07-2025
- Dividend Yield
- DAVA N/A
- FTRE N/A
- EPS Growth
- DAVA 24.14
- FTRE N/A
- EPS
- DAVA 0.49
- FTRE N/A
- Revenue
- DAVA $1,058,028,497.00
- FTRE $2,733,500,000.00
- Revenue This Year
- DAVA $1.48
- FTRE N/A
- Revenue Next Year
- DAVA $5.38
- FTRE N/A
- P/E Ratio
- DAVA $19.06
- FTRE N/A
- Revenue Growth
- DAVA 4.25
- FTRE N/A
- 52 Week Low
- DAVA $9.34
- FTRE $3.97
- 52 Week High
- DAVA $34.94
- FTRE $25.28
- Technical
- Relative Strength Index (RSI)
- DAVA 32.73
- FTRE 62.27
- Support Level
- DAVA $9.34
- FTRE $9.42
- Resistance Level
- DAVA $10.12
- FTRE $10.57
- Average True Range (ATR)
- DAVA 0.58
- FTRE 0.64
- MACD
- DAVA -0.38
- FTRE -0.06
- Stochastic Oscillator
- DAVA 9.03
- FTRE 50.80
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.